Compare PROV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | PEPG |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 121.7M |
| IPO Year | 2009 | 2022 |
| Metric | PROV | PEPG |
|---|---|---|
| Price | $16.84 | $1.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.25 | $11.17 |
| AVG Volume (30 Days) | 6.1K | ★ 625.8K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $25.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.95 | $1.01 |
| 52 Week High | $17.42 | $7.80 |
| Indicator | PROV | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 61.47 |
| Support Level | $16.91 | $1.55 |
| Resistance Level | $17.38 | $5.37 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 78.26 | 98.00 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.